- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies in Cancer: To Be or Not to Be, Selective
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 11, Pages 1591
Publisher
MDPI AG
Online
2021-11-01
DOI
10.3390/biomedicines9111591
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- CFT7455: A NOVEL, IKZF1/3 DEGRADER THAT DEMONSTRATES POTENT TUMOR REGRESSION IN A SPECTRUM OF NHL XENOGRAFT MODELS
- (2021) S Perino et al. HEMATOLOGICAL ONCOLOGY
- Trends in kinase drug discovery: targets, indications and inhibitor design
- (2021) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
- (2021) Meike Kaehler et al. Frontiers in Pharmacology
- Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy
- (2021) Xiaobo Zheng et al. Frontiers in Oncology
- Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine
- (2021) Victor Aaron Sioson et al. Biomedical Engineering Letters
- Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
- (2020) Mi Ran Yun et al. CLINICAL CANCER RESEARCH
- Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
- (2020) LaQuita M. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Emerging agents that target signaling pathways in cancer stem cells
- (2020) Yue Yang et al. Journal of Hematology & Oncology
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
- (2020) Robert Vander Velde et al. Nature Communications
- FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways
- (2020) Cara A. Rabik et al. Annals of Translational Medicine
- A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
- (2020) Adileh Ayati et al. BIOORGANIC CHEMISTRY
- Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review
- (2020) Vida Ebrahimi et al. GENE
- BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
- (2020) Ilaria Proietti et al. Cancers
- Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review
- (2020) Kevin Dzobo et al. Cells
- Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
- (2020) Andrew T. Kuykendall et al. Cancers
- Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
- (2020) Sebastian Scholl et al. Cells
- New Treatment Options for Acute Myeloid Leukemia in 2019
- (2019) Marco Cerrano et al. Current Oncology Reports
- Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems
- (2019) Taegeun Bae et al. Genes & Genomics
- Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
- (2019) Jing Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib and Venetoclax — Doubling Down on CLL
- (2019) Adrian Wiestner NEW ENGLAND JOURNAL OF MEDICINE
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Highlights in Resistance Mechanism Pathways for Combination Therapy
- (2019) Delou et al. Cells
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
- (2019) Stephen B Howell et al. BLOOD
- Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
- (2019) Hussein A. Abbas et al. Cancer Management and Research
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
- (2019) Zuan-Fu Lim et al. Journal of Hematology & Oncology
- Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
- (2019) Joseph A. Clara et al. Nature Reviews Clinical Oncology
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Delivering CRISPR: a review of the challenges and approaches
- (2018) Christopher A. Lino et al. DRUG DELIVERY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A comprehensive review of protein kinase inhibitors for cancer therapy
- (2018) Radhamani Kannaiyan et al. Expert Review of Anticancer Therapy
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Drug and disease signature integration identifies synergistic combinations in glioblastoma
- (2018) Vasileios Stathias et al. Nature Communications
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
- (2017) Paul M. Tyler et al. MOLECULAR CANCER THERAPEUTICS
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- Non-kinase targets of protein kinase inhibitors
- (2017) Lenka Munoz NATURE REVIEWS DRUG DISCOVERY
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
- (2017) Dimpy Koul et al. Oncotarget
- Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development
- (2017) Federica Papaccio et al. Stem Cells Translational Medicine
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Structural Basis for the Non-catalytic Functions of Protein Kinases
- (2016) Jennifer E. Kung et al. STRUCTURE
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
- (2015) Shuang Q. Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Designing a broad-spectrum integrative approach for cancer prevention and treatment
- (2015) Keith I. Block et al. SEMINARS IN CANCER BIOLOGY
- Review article: the biology, diagnosis and management of gastrointestinal stromal tumours
- (2014) N. Iorio et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- IRAK signalling in cancer
- (2014) G W Rhyasen et al. BRITISH JOURNAL OF CANCER
- ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1/WAF1)in human cancer cells
- (2014) Jingru Li et al. BRITISH JOURNAL OF PHARMACOLOGY
- ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells
- (2014) GA BIN PARK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Toll-Like Receptor Signaling Pathways
- (2014) Takumi Kawasaki et al. Frontiers in Immunology
- FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
- (2013) Sabine Kayser et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting cancer stem cells to suppress acquired chemotherapy resistance
- (2013) S J Vidal et al. ONCOGENE
- Epigenetic modifications in cancer
- (2011) R Kanwal et al. CLINICAL GENETICS
- Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma
- (2011) Vito W Rebecca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
- (2011) K C Goh et al. LEUKEMIA
- Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?
- (2011) Dejuan Kong et al. Cancers
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started